Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 13, 2012European Journal of Clinical PharmacologyOpen Access

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

JAJunichi AzumaHyogo University of Health SciencesMOMasako OhnoHyogo University of Health SciencesRKRyuji KubotaShionogi (Japan)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Azuma et al. (2012) studied this question.

synapsesocial.com/papers/69d7773af44a16d01ef3143dhttps://doi.org/10.1007/s00228-012-1429-9
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Low Isoniazid Concentrations and Outcome of Tuberculosis Treatment with Once-Weekly Isoniazid and Rifapentine2003 · 194 citations
  2. 2Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis1976 · 135 citations
  3. 3Polymorphism of the N -acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis2002 · 434 citations
  4. 4Genetical and Geographic Studies on Isoniazid Inactivation1961 · 132 citations